Your browser doesn't support javascript.
loading
High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?
Pophali, Priyanka A; Marinelli, Lisa M; Ketterling, Rhett P; Meyer, Reid G; McPhail, Ellen D; Kurtin, Paul J; Mwangi, Raphael; Maurer, Matthew J; Habermann, Thomas; King, Rebecca L.
Afiliação
  • Pophali PA; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
  • Marinelli LM; Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Ketterling RP; Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Meyer RG; Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • McPhail ED; Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Kurtin PJ; Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Mwangi R; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Maurer MJ; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Habermann T; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
  • King RL; Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. rebecca.king98@gmail.com.
Blood Cancer J ; 10(1): 5, 2020 01 13.
Article em En | MEDLINE | ID: mdl-31932576
ABSTRACT
While MYC translocations in B-cell lymphoma (BCL) have been extensively studied, the significance of MYC amplification (MYC amp) is poorly understood. This study characterizes BCL showing MYC amp, defined as uncountable FISH signals. Retrospective analysis of all BCL FISH for MYC aberrations performed at our institution (1/2010-2/2018) identified 44/9715 (0.45%) cases with MYC amp. MYC amp probe signals appeared in a cloud-like distribution (70%) or in a single homogenous-staining-region (30%). In total 59% also had MYC separation by breakapart probe indicating concurrent MYC translocation. The most common morphology was large cell (82%) and diagnosis was diffuse large BCL (DLBCL, 50%). In total 88% were germinal center B-cell-like by Hans algorithm. In total 12/42 (29%) cases were "double-hit" by WHO criteria (DHL/THL) in addition to having MYC amp. The estimated 2-year overall survival (OS) of DLBCL cases with MYC amp was 80%. There was no significant difference in OS between DLBCL and DHL/THL among cases with MYC amp, suggesting a poor prognostic impact of MYC amp. However, when compared to a larger cohort of DLBCL and DHL/THL, MYC amp did not have prognostic significance. In summary, MYC amp in BCL is rare, most commonly occurs in DLBCL, and was not associated with survival in our cohort.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Genes myc / Linfoma Difuso de Grandes Células B Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Genes myc / Linfoma Difuso de Grandes Células B Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article